The 36-month beta value for ESPR is also noteworthy at 0.78. There are mixed opinions on the stock, with 2 analysts rating it as a “buy”, 2 rating it as “overweight”, 2 rating it as “hold”, and 0 rating it as “sell”.
The public float for ESPR is 194.62M, and at present, short sellers hold a 12.39% of that float. The average trading volume of ESPR on July 08, 2025 was 5.07M shares.
ESPR stock’s latest price update
The stock of Esperion Therapeutics Inc (NASDAQ: ESPR) has increased by 8.56% when compared to last closing price of $1.11.Despite this, the company has seen a gain of 22.41% in its stock price over the last five trading days. globenewswire.com reported 2025-07-01 that Brings More Than Twenty Years of Biopharmaceutical Leadership Experience Brings More Than Twenty Years of Biopharmaceutical Leadership Experience
ESPR’s Market Performance
Esperion Therapeutics Inc (ESPR) has experienced a 22.41% rise in stock performance for the past week, with a 3.88% rise in the past month, and a -2.03% drop in the past quarter. The volatility ratio for the week is 9.03%, and the volatility levels for the past 30 days are at 7.21% for ESPR. The simple moving average for the past 20 days is 8.64% for ESPR’s stock, with a -29.66% simple moving average for the past 200 days.
Analysts’ Opinion of ESPR
Many brokerage firms have already submitted their reports for ESPR stocks, with Goldman repeating the rating for ESPR by listing it as a “Neutral”. The predicted price for ESPR in the upcoming period, according to Goldman is $4 based on the research report published on December 18, 2024 of the previous year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see ESPR reach a price target of $8. The rating they have provided for ESPR stocks is “Overweight” according to the report published on December 17th, 2024.
ESPR Trading at 21.52% from the 50-Day Moving Average
After a stumble in the market that brought ESPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.42% of loss for the given period.
Volatility was left at 7.21%, however, over the last 30 days, the volatility rate increased by 9.03%, as shares sank -1.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.16% upper at present.
During the last 5 trading sessions, ESPR rose by +21.90%, which changed the moving average for the period of 200-days by -32.58% in comparison to the 20-day moving average, which settled at $1.1089. In addition, Esperion Therapeutics Inc saw -48.94% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ESPR starting from Looker Benjamin, who sold 6,422 shares at the price of $1.15 back on Jun 17 ’25. After this action, Looker Benjamin now owns 401,241 shares of Esperion Therapeutics Inc, valued at $7,398 using the latest closing price.
Koenig Sheldon L., the President and CEO of Esperion Therapeutics Inc, sale 30,474 shares at $1.11 during a trade that took place back on Jun 17 ’25, which means that Koenig Sheldon L. is holding 1,541,488 shares at $33,796 based on the most recent closing price.
Stock Fundamentals for ESPR
Current profitability levels for the company are sitting at:
- -0.15% for the present operating margin
- 0.65% for the gross margin
The net margin for Esperion Therapeutics Inc stands at -0.59%. The total capital return value is set at -0.75%.
Based on Esperion Therapeutics Inc (ESPR), the company’s capital structure generated -2.32 points at debt to capital in total, while cash flow to debt ratio is standing at -0.34. The debt to equity ratio resting at -0.7. The interest coverage ratio of the stock is -0.62.
Currently, EBITDA for the company is 7.57 million with net debt to EBITDA at -2.07. When we switch over and look at the enterprise to sales, we see a ratio of 1.62. The receivables turnover for the company is 3.19for trailing twelve months and the total asset turnover is 0.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.18.
Conclusion
In summary, Esperion Therapeutics Inc (ESPR) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
